LBPO.PS01 · 人群科学 · Late-Breaking
脊索瘤的发病模式和时间趋势：一项对美国超过6000例病例的基于人群的分析
Incidence patterns and temporal trends of chordoma: A population-based analysis of over 6000 cases in the United States
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：脊索瘤是一种起源于脊索残余的罕见恶性骨肿瘤，病因大多未知，描述性特征刻画有限。
方法：使用来自北美中央癌症登记处协会（覆盖93%美国人口）的数据，按人口学和临床因素估计2003-2022年的年龄标准化发病率和趋势。使用Joinpoint回归量化期间趋势，使用年龄-期间-队列建模评估出生队列趋势。使用来自21个监测、流行病学与最终结果（SEER）登记处的数据，估计2003-2021年诊断病例的相对生存率。
结果：在2003-2022年期间共诊断了6,260例脊索瘤病例。颅部肿瘤最为常见（38.7%），其次是骶部（32.7%）和脊柱（25.4%）部位。年龄标准化发病率为0.097/100,000，随年龄增加并在80-84岁达到峰值。男性在35岁后的发病率高于女性。发病率在黑人个体中最低，在东北部和大都市地区最高。2003-2022年间，发病率每年上升1.47%（95% CI = 0.61-2.39），在较年轻个体、女性以及局限期和颅部肿瘤中上升更为陡峭。相继的出生队列显示风险增加，1998年前后出生者的率约为1958年前后出生者的两倍（95% CI = 1.28-3.16）。在2,181例SEER病例中，5年相对生存率为83.4%，因种族/民族和地区而异，对于远处分期疾病，其范围从68.6%（颅部）到38.3%（骶部）。
结论：脊索瘤的发病率和生存率因人口学和临床因素而异，提示在检测、医疗可及性和潜在病因方面可能存在差异。
查看英文原文 English abstract
Background: Chordoma is a rare malignant bone tumor arising from notochordal remnants, with largely unknown etiology and limited descriptive characterization.
Methods: Data from the North American Association of Central Cancer Registries, covering 93% of the U.S. population, were used to estimate age-standardized incidence rates and trends from 2003-2022 by demographic and clinical factors. Period trends were quantified using Joinpoint regression, and birth-cohort trends were assessed using age-period-cohort modeling. Data from 21 Surveillance, Epidemiology, and End Results (SEER) registries were used to estimate relative survival for cases diagnosed from 2003-2021.
Results: A total of 6,260 chordoma cases were diagnosed during 2003-2022. Cranial tumors were most frequent (38.7%), followed by sacral (32.7%) and spinal (25.4%) sites. The age-standardized incidence rate was 0.097 per 100,000, increasing with age and peaking at 80-84 years. Males had higher incidence than females after age 35. Incidence was lowest among Black individuals and highest in the Northeast and metropolitan areas. From 2003-2022, incidence rose 1.47% annually (95% CI = 0.61-2.39), with steeper increases among younger individuals, women, and localized and cranial tumors. Successive birth cohorts showed increasing risk, with those born near 1998 having approximately twice the rate of those born near 1958 (95% CI = 1.28-3.16). Among 2,181 SEER cases, 5-year relative survival was 83.4%, varying by race/ethnicity and region, and for distant-stage disease ranged from 68.6% (cranial) to 38.3% (sacral).
Conclusions: Chordoma incidence and survival vary by demographic and clinical factors, suggesting potential differences in detection, healthcare access, and underlying etiology.
利益披露 Disclosure
H. Sung, None..
C. Jiang, None..
H. Koka, None..
J. Bai, None..
A. Goldstein, None..
X. Yang, None.